Cargando…
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
BACKGROUND: The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs. MATERIALS AND METHODS: Data on survival and health care resource use were retrieved from the Dutch Melanoma Treatment Registry....
Autores principales: | Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., Uyl-de Groot, C.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639434/ https://www.ncbi.nlm.nih.gov/pubmed/34856511 http://dx.doi.org/10.1016/j.esmoop.2021.100320 |
Ejemplares similares
-
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
por: Leeneman, Brenda, et al.
Publicado: (2020) -
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
por: Verver, Danielle, et al.
Publicado: (2021) -
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020) -
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study
por: van der Kooij, Monique K., et al.
Publicado: (2021) -
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)